Physician profile
Robert A Stetson
NPI 1891729927
$2,178.05
in general payments reported to CMS, 2019-2025
19 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $852 · 2021: $109 · 2022: $380 · 2023: $148 · 2024: $33.90 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $537.47 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $267.93 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $208.53 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $205.57 | 2019-2023 | Austedo, Austedo Xr |
| Abbvie INC. | $162.79 | 2021-2023 | Vraylar |
| Lundbeck LLC | $147.32 | 2019-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $131.82 | 2019-2020 | |
| Allergan, INC. | $94.54 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.95 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $58.46 | 2019-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $57.72 | 2022-2025 | Qelbree |
| Alkermes, INC. | $48.01 | 2022-2023 | Lybalvi |
| Shire North American Group INC | $36.44 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.61 | 2020 | |
| Neuronetics, INC. | $31.42 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $20.86 | 2019 | |
| Corium, LLC | $20.02 | 2024-2025 | Azstarys |
| Eisai INC. | $17.05 | 2020 | |
| Almatica Pharma LLC | $16.54 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stetson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.